RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced initial results of a Phase 1 study assessing the tolerability, safety, and pharmacokinetics of Bioral™ Amphotericin B, BDSI’s lead product candidate utilizing the company’s Bioral drug delivery technology.
